- Home
- GFL vs MDGL Comparison
GFL vs MDGL Comparison
Compare GFL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFL | MDGL |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 12.4B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GFL | MDGL |
|---|---|---|
| Price | $39.63 | $534.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $55.22 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.9M | 307.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $8.18 | $58.39 |
| Revenue Next Year | $7.20 | $48.55 |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.33 | $286.75 |
| 52 Week High | $51.51 | $615.00 |
Technical Indicators
Market Signals| Indicator | GFL | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 55.61 |
| Support Level | $38.60 | $535.33 |
| Resistance Level | $45.94 | $545.29 |
| Average True Range (ATR) | 1.18 | 23.48 |
| MACD | 0.07 | 0.83 |
| Stochastic Oscillator | 65.99 | 54.32 |
Price Performance
Historical ComparisonAbout GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.